Harnessing the beneficial properties of adipogenic microbes for improving human health

Summary Obesity is associated with numerous metabolic comorbidities. Weight loss is an effective measure for alleviating many of these metabolic abnormalities. However, considering the limited success of most medical weight‐management approaches in producing a sustained weight loss, approaches that...

Full description

Saved in:
Bibliographic Details
Published inObesity reviews Vol. 14; no. 9; pp. 721 - 735
Main Authors Dhurandhar, N. V., Geurts, L., Atkinson, R. L., Casteilla, L., Clement, K., Gerard, P., Vijay-Kumar, M., Nam, J. H., Nieuwdorp, M., Trovato, G., Sørensen, T. I. A., Vidal-Puig, A., Cani, P. D.
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 01.09.2013
Wiley Subscription Services, Inc
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Summary Obesity is associated with numerous metabolic comorbidities. Weight loss is an effective measure for alleviating many of these metabolic abnormalities. However, considering the limited success of most medical weight‐management approaches in producing a sustained weight loss, approaches that improve obesity‐related metabolic abnormalities independent of weight loss would be extremely attractive and of practical benefit. Metabolically healthy obesity supports the notion that a better metabolic profile is possible despite obesity. Moreover, adequate expansion of adipose tissue appears to confer protection from obesity‐induced metabolic comorbidities. To this end, the 10th Stock conference examined new approaches to improve metabolic comorbidities independent of weight loss. In particular, human adenovirus 36 (Ad36) and specific gut microbes were examined for their potential to influence lipid and glucose homeostasis in animals and humans. While these microbes possess some undesirable properties, research has identified attributes of adenovirus Ad36 and gut microbes that may be selectively harnessed to improve metabolic profile without the obligatory weight loss. Furthermore, identifying the host signalling pathways that these microbes recruit to improve the metabolic profile may offer new templates and targets, which may facilitate the development of novel treatment strategies for obesity‐related metabolic conditions.
Bibliography:Vital Health Interventions, LLC
Nutricia Research Foundation
istex:45B7D61A886B3E24F5D1A40C91783EBC0CD14998
ark:/67375/WNG-SGRDBFC5-6
Ministry of Education, Science and Technology - No. 2012039819
SFD (Société Francophone du Diabète, France)
FRSM (Fonds de la Recherche Scientifique Médicale, Belgium)
ArticleID:OBR12045
ARC (Action de Recherche Concertée)
FSR (fonds spéciaux de recherche, Université catholique de Louvain, Belgium)
Patent filed
November 2006. File no. 05P09. Adenovirus Ad36 E4orf1 protein for prevention and treatment of non‐alcoholic fatty liver disease. U.S. patent application 8 July 2010. 61/362,443; Taiwan.
Patent number 100124173. Enhanced glycaemic control using Ad36E4orf1 and AKT1 Inhibitor. January 2013.
Dhurandhar NV and Holland TC. Ad‐36 E4 orf‐1, E1A and obesity and diabetes.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Feature-3
ObjectType-Review-1
ISSN:1467-7881
1467-789X
DOI:10.1111/obr.12045